* AtriCure Inc ATRC.OQ ATRC.O is expected to show a rise
in
quarterly revenue when it reports results on November 1.
* The Mason Ohio-based company is expected to report a
15.4% increase in revenue to $81.329 million from $70.46 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for AtriCure Inc is for
a
loss of 25 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AtriCure
Inc is
$65, above its last closing price of $40.51.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.29 -0.29 -0.32 Missed -9.3
Mar. 31 2022 -0.31 -0.32 -0.33 Missed -3.2
Dec. 31 2021 -0.29 -0.29 -0.30 Missed -3.4
Sep. 30 2021 -0.33 -0.32 2.11 Beat 750
Jun. -0.34 -0.33 -0.36 Missed -7.5
30 2021
Mar. 31 2021 -0.37 -0.37 -0.38 Missed -3.5
Dec. 31 2020 -0.27 -0.28 -0.28 Met 0.6
Sep. 30 2020 -0.32 -0.34 -0.11 Beat 67.6
This summary was machine generated October 28 at 22:07 GMT. All
figures in US dollars unless otherwise stated